Talazoparib and Temozolomide in Treating Younger Patients With Refractory or Recurrent Malignancies
Status:
Completed
Trial end date:
2018-12-31
Target enrollment:
Participant gender:
Summary
This phase I/II trial studies the side effects and best dose of talazoparib and temozolomide
and to see how well they work in treating younger patients with tumors that have not
responded to previous treatment (refractory) or have come back (recurrent). Talazoparib may
stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs
used in chemotherapy, such as temozolomide, work in different ways to stop the growth of
cancer cells, either by killing the cells, by stopping them from dividing, or by stopping
them from spreading. Giving talazoparib together with temozolomide may work better in
treating younger patients with refractory or recurrent malignancies.